Baruchel et al., have demonstrated that non-denatured whey protein isolate increased lymphocyte intracellular glutathione by greater than 120% in mice compared to mice fed standard, commercially available whey protein concentrates, or casein proteins. Similarly, Kennedy et al., demonstrated that non-denatured whey protein isolate increased glutathione in normal cells, but decreased glutathione in cancer cells. It has been proposed that cancer cells produce more intracellular glutathione than normal cells to protect themselves from various reactive oxygen species. Thus, it is possible that the ingestion of non-denatured whey protein isolates may oxidatively stress cancer cells, while protecting normal cells. This may be why carcinogen-treated mice fed non-denatured whey protein isolates had significantly smaller tumor burdens than controls. Wasting (cachexia) can also be a significant problem for the cancer patient. Although the mechanisms of cachexia are not fully understood, there are major metabolic alterations in the cancer patient and tumor cells usually resort to anaerobic rather than aerobic metabolism for the production of energy. This type of metabolism is grossly inefficient and generates large amounts of lactic acid that must, in turn, be regenerated back into glucose in the liver. Cachexia is also characterized by decreased appetite. IMUPlus supplies the patient with a perfectly balanced protein source without the need for large volumes of food and without the added burden of saturated fat solids or lactose associated with other milk protein sources.

CONTRAINDICATIONS and WARNINGS
IMUPlus is contraindicated in individuals who develop or have known hypersensitivity to specific milk proteins. IMUPlus contains <0.05% lactose and is generally well tolerated by lactose-intolerant individuals. Patients undergoing immunosuppressive therapy should discuss the use of this product with their health professional.

ADVERSE REACTIONS
Gastrointestinal bloating and cramps can occur if the product is not sufficiently rehydrated. Transient urticarial-like rash has been seen in rare individuals undergoing severe detoxification reaction. Such rashes were found to abate when product intake is stopped or reduced.

OVERDOSE
Overdosing on IMUPlus has not been reported. Unless hypersensitive to milk constituents, no toxicity of milk proteins has been described.

DOSAGES & ADMINISTRATION
Maintenance dose is 2 packets (20 grams) per day. For mild to moderate health challenges, higher doses are recommended. Clinical trials in patients with cancer, chronic fatigue syndrome, hepatitis and AIDS have used 30-50 grams per day.

DIRECTIONS
Take packet #1 at least 30 minutes before eating in the morning. Take packet #2 between 3-4 p.m. or, as directed by a health professional.
Fill a large glass with 6 ounces of distilled water -or- combine a compatible protein (milk, soy milk, almond milk and yogurt) with the distilled water. Empty a packet of IMUPlus into the liquid. Using a fork stir until mixture thickens. Let stand 5-10 minutes to rehydrate the formula, stir again and drink. (instructions are on packaging).
For easy mixing use our Portable Mixer designed to preserve the non-denatured quality of IMU Plus ™.

CAUTION
Do not mix with fruit juice or heated liquids. Never mix in a conventional electric mixer/blender, as this will denature the IMUPlus bioactive proteins.

NOTE: - IMUPlus is a natural food supplement, and as such is limited from stating medical claims per se. Statements have not been evaluated by the FDA. As such, this product is not intended to diagnose, cure, prevent or treat any disease.
HOW SUPPLIED
One 600 gram carton contains 60, 10 gram packets.

Gutman, J. Schettini, S., The ultimate GSH 3. Handbook. Montreal: Gutman and Schettini Enr. 1998
Baruchel, S, Viav, G., Oliver. R., Bounous, G., Wainberg, MA. Nutraceutical modulation of GSH with a humanized native milk serum protein isolate. Marcel Deker Inc. New York, 1996
Meister A. New aspects of glutathione biochemistry and transport, selective alteration of glutathione metabolism. Nutr Rev 42:397-410, 1984.
Kaplowitz N, Aw T, Opkhtens M. The regulation of hepatic glutathione. Ann Rev Pharmacol Toxicoil 25:715-44, 1985.
Kennedy R, Knok G, Bounous G, Baruchel S, Lee T. The use of a whey protein in the treatment of patients with matastatic carcinoma: A phase i-ii clinical study. Anticancer Research 15:2643-50.1995.
Watanabe A, Higuichi K, Yasumura S, Shimizu Y, Kondo Y, Kohri H. Nutritional modulation of glutathione level and cellular immunity in chronic hepatitis B and C. Hepatology. 24:597A, 1996
Lomaestro B. Malone M. Glutathione in health and diseases: Pharmacotherapeutic Issues. Ann Pharmacother 29:1267-73, 1995
Lothian B, Grey V, Kimoff RJ, Lands LC. Treatment of obstructive airway disease with a cysteine donor protein supplement: a case report. Chest 117:914-916. 2000.